NephJC Shorts

Nephrology produces far more new studies each week than NephJC can realistically cover in its twice‑monthly full reviews. That’s why we’re introducing NephJC Short- quick, sharp summaries of notable papers that caught the editorial team’s attention. Suggestions welcome, and feedback too.

🩳Read more on the blog post describing this initiative.


Upcoming NephJC Shorts

  • Finerenone in Patients With Chronic Kidney Disease Due to Glomerular Diseases: A Randomized Clinical Trial (Neuen BL et al, JAMA, 2026)
    Efficacy and safety of finerenone in patients with chronic kidney disease: an individual participant data pooled analysis (INFINITY) (Neuen BL, Lancet, 2026)

  • Nondialyzable versus Dialyzable Beta-Blockers in Hemodialysis (Etemadi A et al, JASN, 2026)

  • Atrasentan in patients with IgA nephropathy (ALIGN): final 2·5-year results from a randomised, double-blind, placebo-controlled, phase 3 trial (Heerspink HJL et al, Lancet, 2026)

  • Vasopressors or Fluids in Early Septic Shock (ARISE Fluids investigators, NEJM, 2026)

  • Increasing Plasma Sodium with Tolvaptan Under Regulated Water Intake (Sweis NW et al, Am J Physiol Renal Physiol. 2026)